On January 31, 2023, a TASS press conference was held dedicated to the joint scientific and technological developments of the Ural State Medical University and industrial enterprises of the Sverdlovsk Region. The results of the implementation of the Priority 2030 program in 2022, the cooperation of the university with industrial enterprises of the region, as well as the project for creation of a full-cycle scientific and educational complex for the manufacture of medicines were discussed by Olga Kovtun, rector of USMU, Anatoly Sludnykh, General Director of the Ural Optical and Mechanical Plant, and Alexander Petrov, Chairman of the Board of Directors of the Medsintez Plant.
On November 26, 2022, the Medsintez Plant took part in the Scientific and Practical Conference of Pediatric Endocrinologists of the Sverdlovsk Region From Clinical Cases to Innovative Projects, dedicated to the 25th anniversary of the endocrinology department of the Regional Children's Clinical Hospital. Leading experts of Russia in the field of healthcare and endocrinology took part in the conference. At the exhibition of domestic pharmaceutical manufacturers, held within the framework of the conference, the Medsintez Plant presented analogue human insulin preparations Rosinsulin®. Doctors – pediatric endocrinologists and endocrinologists of healthcare organizations of the Sverdlovsk Region, the Ural Federal District and other regions of Russia noted the plant's contribution to the drug safety of the country.
On November 19, 2022, the Medsintez Plant, which has the highest FSH production capacity in the world, held a grand opening of the workshop for the production of biotechnological substances for women's reproductive health. Since 2018, the Medsintez Plant, in cooperation with iVFarma, has been producing the first Russian preparation of recombinant follicle-stimulating hormone (FSH) for the treatment of human infertility – Primapur®. The Medsintez Plant produces the substance of this drug and the finished dosage form in pre-filled disposable syringe pens.
On September 12, a press conference was held at the press center of the Interfax News Agency in Ekaterinburg, dedicated to the epidemiological situation, as well as new research on the treatment of acute respiratory viral infections in children in the Sverdlovsk Region. At the moment, multicenter, randomized, double-blind, comparative, placebo-controlled clinical trials of the efficacy and safety of Triazavirin in 12-17 year old children with ARVI diagnosis have been completed.
From September 5 to 8, 2022, the IX (XXVIII) National Diabetes Congress with international participation Diabetes Mellitus and Obesity – the Non-Infectious Interdisciplinary Pandemics of the 21st Century was held in Moscow, organized by the Russian Association of Endocrinologists and the Federal State Budgetary Institution National Medical Research Center for Endocrinology of the Ministry of Health of Russia. Among the leading domestic and foreign companies producing medicines, the Medsintez Plant presented its main products at the booth – preparations of genetically engineered and analogue human insulin Rosinsulin.
